These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 23560463)

  • 1. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
    Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
    Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
    Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
    J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection.
    Lioté F; Pertuiset E; Cochand-Priollet B; D'Agay MF; Dombret H; Numéric P; D'Anglejan G; Kuntz D
    J Rheumatol; 1995 Jun; 22(6):1174-8. PubMed ID: 7674250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders.
    Yamakawa N; Fujimoto M; Kawabata D; Terao C; Nishikori M; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Ohmura K; Fujii T; Kitano T; Kondo T; Yurugi K; Miura Y; Maekawa T; Saji H; Takaori-Kondo A; Matsuda F; Haga H; Mimori T
    J Rheumatol; 2014 Feb; 41(2):293-9. PubMed ID: 24334644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection.
    Miyazaki T; Fujimaki K; Shirasugi Y; Yoshiba F; Ohsaka M; Miyazaki K; Yamazaki E; Sakai R; Tamaru J; Kishi K; Kanamori H; Higashihara M; Hotta T; Ishigatsubo Y
    Am J Hematol; 2007 Dec; 82(12):1106-9. PubMed ID: 17654684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders.
    Ejima-Yamada K; Oshiro Y; Okamura S; Fujisaki T; Mihashi Y; Tamura K; Fukushige T; Kojima M; Shibuya K; Takeshita M
    Virchows Arch; 2017 Feb; 470(2):205-215. PubMed ID: 27864689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
    Salloum E; Cooper DL; Howe G; Lacy J; Tallini G; Crouch J; Schultz M; Murren J
    J Clin Oncol; 1996 Jun; 14(6):1943-9. PubMed ID: 8656264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics and rituximab addition to cytotoxic therapies in patients with rheumatoid arthritis and methotrexate-associated large B lymphoproliferative disorders.
    Yamada K; Oshiro Y; Okamura S; Fujisaki T; Kondo S; Nakayama Y; Suematsu E; Tamura K; Takeshita M
    Histopathology; 2015 Jul; 67(1):70-80. PubMed ID: 25429725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
    Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
    Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate-related Epstein-Barr virus-associated lymphoproliferative disorder occurring in the gingiva of a patient with rheumatoid arthritis.
    Ishida M; Hodohara K; Yoshii M; Okuno H; Horinouchi A; Nakanishi R; Harada A; Iwai M; Yoshida K; Kagotani A; Yoshida T; Okabe H
    Int J Clin Exp Pathol; 2013; 6(10):2237-41. PubMed ID: 24133604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types.
    Gion Y; Iwaki N; Takata K; Takeuchi M; Nishida K; Orita Y; Tachibana T; Yoshino T; Sato Y
    Cancer Sci; 2017 Jun; 108(6):1271-1280. PubMed ID: 28380678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
    Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
    Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous regression of breast lymphoproliferative disorders after withdrawal of methotrexate in rheumatoid arthritis patients with Epstein-Barr virus infection: a case report and review of the literature.
    Ogawa A; Nakagawa T; Kumaki Y; Hosoya T; Oda G; Mori M; Fujioka T; Kubota K; Onishi I; Uetake H
    J Med Case Rep; 2022 Feb; 16(1):49. PubMed ID: 35125110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: A clinicopathologic and immunophenotypical study of 10 cases.
    Koens L; Senff NJ; Vermeer MH; Willemze R; Jansen PM
    Am J Surg Pathol; 2014 Jul; 38(7):999-1006. PubMed ID: 24805861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-related lymphoma in rheumatoid arthritis: implications for long-term usage of immunosuppressive drugs and review of the literature.
    He J; Williamson L; Cai K; Wong P; Sturgess A; Taper J; Manolios N
    Intern Med J; 2022 Oct; 52(10):1717-1723. PubMed ID: 34028145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate.
    Kondo S; Tanimoto K; Yamada K; Yoshimoto G; Suematsu E; Fujisaki T; Oshiro Y; Tamura K; Takeshita M; Okamura S
    Virchows Arch; 2013 Apr; 462(4):399-407. PubMed ID: 23494713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjögren's syndrome: case series.
    Dawson TM; Starkebaum G; Wood BL; Willkens RF; Gown AM
    J Rheumatol; 2001 Jan; 28(1):47-53. PubMed ID: 11196542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological findings, prognosis, and Epstein-Barr virus infection in rheumatoid arthritis patients with other iatrogenic immunodeficiency-associated T- and NK-cell lymphoproliferative disorders.
    Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Ogata M; Daa T; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
    BMC Cancer; 2022 Dec; 22(1):1342. PubMed ID: 36544095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
    Harada T; Iwasaki H; Muta T; Urata S; Sakamoto A; Kohno K; Takase K; Miyamura T; Sawabe T; Asaoku H; Oryoji K; Fujisaki T; Mori Y; Yoshimoto G; Ayano M; Mitoma H; Miyamoto T; Niiro H; Yamamoto H; Oshiro Y; Miyoshi H; Ohshima K; Takeshita M; Akashi K; Kato K
    Br J Haematol; 2021 Jul; 194(1):101-110. PubMed ID: 33822354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection.
    Hoshida Y; Tomita Y; Zhiming D; Yamauchi A; Nakatsuka S; Kurasono Y; Arima Y; Tsudo M; Shintaku M; Aozasa K
    Int J Cancer; 2004 Jan; 108(3):443-9. PubMed ID: 14648712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.